Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Gross Margin (2022 - 2026)

Axsome Therapeutics' Gross Margin history spans 5 years, with the latest figure at 92.3% for Q1 2026.

  • On a quarterly basis, Gross Margin rose 36.0% to 92.3% in Q1 2026 year-over-year; TTM through Mar 2026 was 92.6%, a 432.0% increase, with the full-year FY2025 number at 92.56%, up 120.0% from a year prior.
  • Gross Margin hit 92.3% in Q1 2026 for Axsome Therapeutics, down from 93.71% in the prior quarter.
  • Over the last five years, Gross Margin for AXSM hit a ceiling of 93.71% in Q4 2025 and a floor of 2002.8% in Q4 2024.
  • Historically, Gross Margin has averaged 39.87% across 5 years, with a median of 90.9% in 2025.
  • Biggest five-year swings in Gross Margin: crashed -209249bps in 2024 and later surged 209651bps in 2025.
  • Tracing AXSM's Gross Margin over 5 years: stood at 90.6% in 2022, then decreased by -1bps to 89.69% in 2023, then tumbled by -2333bps to 2002.8% in 2024, then soared by 105bps to 93.71% in 2025, then dropped by -2bps to 92.3% in 2026.
  • Business Quant data shows Gross Margin for AXSM at 92.3% in Q1 2026, 93.71% in Q4 2025, and 93.03% in Q3 2025.